Chronic and non-canonical cGAS-STING activation: implications for health, disease, cancer, and emerging therapeutic opportunities - PubMed
3 months ago
- #cGAS-STING pathway
- #Cancer treatment
- #Immunotherapy
- Immunotherapy, including CAR T cells and STING agonists, is emerging as a novel approach for cancer treatment.
- Dysregulated or chronic activation of the cGAS-STING pathway contributes to various human pathological conditions.
- cGAS recognizes cytoplasmic dsDNA and generates 2'3' cGAMP, which activates STING and downstream pathways like TBK1 to IRF-3 and NF-κB.
- The cGAS-STING pathway is traditionally associated with antiviral immune responses but also has non-canonical pathways linked to diseases and cancer survival.
- Chronic and non-canonical cGAS-STING activation is associated with human diseases and cancer, presenting therapeutic opportunities.
- STING agonists and inhibitors, as well as cGAS inhibitors, are being explored for their therapeutic potential.